

One-Pot Synthesis and Surface Modification of Lauric-Acid-Capped CoFe₂O₄ Nanoparticles

Yun Teng¹ and Philip W. T. Pong

Department of Electrical and Electronic Engineering, The University of Hong Kong, Hong Kong

This paper presents a facile one-pot method to synthesize monodisperse lauric-acid-capped cobalt ferrite nanoparticles (CoFe₂O₄ NPs) and investigates their potential application as drug carriers for loading and controlled release of doxorubicin (DOX). The lauric-acid-capped CoFe₂O₄ NPs with a particle size of 15.3 ± 1.7 nm were synthesized via one-pot reaction. Water-soluble lauric-acid-capped CoFe₂O₄ NPs were obtained through surface modification with cetyltrimethylammonium bromide (CTAB) and sodium dodecyl sulfate (SDS). Furthermore, the performance of water-soluble lauric-acid-capped CoFe₂O₄ NPs for drug delivery was investigated with DOX hydrochloride. The DOX release percentages of CTAB and SDS modified lauric-acid-capped CoFe₂O₄ NPs are 56.1% and 48.2%, respectively. These results indicated that the modified lauric-acid-capped CoFe₂O₄ NPs could be utilized as a promising candidate for cancer chemotherapy by making use of their pH-sensitive drug-release properties.

Index Terms—Drug delivery, inverse spinel cobalt ferrite (CoFe₂O₄), one-pot method, surface modification.

I. INTRODUCTION

MAGNETIC nanoparticles (NPs) of ferrites have a wide range of applications owing to their particular physico-chemical properties and large surface to volume ratio [1], [2], which are different from the bulk materials. The inverse spinel cobalt ferrite (CoFe₂O₄) has attracted enormous attention because they have high intrinsic magnetocrystalline anisotropy and large coercivity [3], [4], which can cause a higher heat dissipation than other ferrite NPs with similar size [5]. Thus, they can be used to induce magnetic hyperthermia for various applications [6]–[8]. Several synthesis methods of CoFe₂O₄ NPs have been reported previously [9]–[12]. For example, the coprecipitation method has been widely used because of its easy operation and high yield [13]. However, the reported methods involve multiple-step syntheses which are more complicated and time-consuming to obtain the desired resulting NPs. Therefore, producing CoFe₂O₄ NPs with an efficient and facile route is still challenging and greatly desired. Typically, the hydrophobic organic ligands (such as oleic acid) coated on the surfaces of the nanocrystalline structures [14] limit the range of biomedical applications of these NPs by making them difficult to disperse in water. The surface modification of CoFe₂O₄ NPs through surfactant addition and surfactant exchange can improve their water solubility [15], [16]. This is of great importance for their future biomedical applications [17], [18], such as drug delivery which inquires great water solubility of NPs.

In this paper, a facile one-pot method was developed for the synthesis of lauric-acid-capped CoFe₂O₄ NPs with promising stability and uniformity, and the NPs were further transferred into aqueous phase through surface modification using surfactants including cetyltrimethylammonium

bromide (CTAB) and sodium dodecyl sulfate (SDS). These water-soluble CoFe₂O₄ NPs can be directly functionalized with target biomolecules to be applied in an aqueous environment for biosensing, protein separation, and drug delivery [19]–[21]. Finally, the modified lauric-acid-capped CoFe₂O₄ NPs were applied to loading and *in vitro* controlled release of doxorubicin (DOX) hydrochloride. This system shows great promise for biomedical applications, especially for targeted cancer therapy.

II. EXPERIMENT

A. Materials

The synthesis was carried out using commercially available reagents. Cyclohexene, phenyl oleylamine (>70%), CTAB, sodium ether (99%), 1, 2-tetradecanediol (97%), oleic acid (90%), dodecyl sulfate (SDS), phosphate buffer saline (PBS), and DOX hydrochloride were purchased from Aldrich Chemical Co., Milwaukee, WI, USA. Lauric acid was purchased from Sigma-Aldrich Fine Chemicals, St. Louis, MO, USA. Iron (III) acetylacetonate and cobalt (II) acetylacetonate were purchased from Acros. They were used as received without any further purification. Distilled deionized water was used for the experiment in aqueous solutions. All the chemicals were used as received.

B. Synthesis of Lauric-Acid-Capped CoFe₂O₄ Nanoparticles

The monodisperse lauric-acid-capped CoFe₂O₄ NPs were synthesized via one-pot reaction following the literature protocol, as shown in Fig. 1 [22]. Co(acac)₂ (1 mmol), Fe(acac)₃ (2 mmol), 1, 2-tetradecanediol (10 mmol), oleic acid (6 mmol), oleylamine (6 mmol), and phenyl ether (20 mL) were mixed with lauric acid (6 mmol), and the mixture was magnetically stirred under nitrogen. The mixture was heated to 200 °C for 1.5 h and then heated to reflux at 280 °C for 1 h. After cooled to room temperature by removing the heating source, the mixture was purified by precipitating and dissolving operations using acetone and chloroform solvent for several times to remove excessive surfactants. The products were dissolved in 12 mL cyclohexene for further use.

Manuscript received March 16, 2018; revised April 16, 2018; accepted April 24, 2018. Date of publication May 30, 2018; date of current version October 17, 2018. Corresponding author: P. W. T. Pong (e-mail: ppong@eee.hku.hk).

Color versions of one or more of the figures in this paper are available online at <http://ieeexplore.ieee.org>.

Digital Object Identifier 10.1109/TMAG.2018.2834524




Fig. 1. Schematic of synthesis process for lauric-acid-capped CoFe₂O₄ NPs and DOX loading and releasing processes.

C. Surface Modification of Lauric-Acid-Capped CoFe₂O₄ Nanoparticles

The as-synthesized lauric-acid-capped CoFe₂O₄ NPs were transferred to water using CTAB and SDS, respectively, following the protocol developed in [23]. A 0.5 g of lauric-acid-capped CoFe₂O₄ NPs were added to a suspension of CTAB and SDS in deionized water with the concentration of 10 mg·mL⁻¹, respectively, and the mixture was stirred for 2 h at 75 °C to obtain a modified water-based CoFe₂O₄ solution. Finally, the precipitate was collected by centrifugation and washed with deionized water for several times. The particles were redispersed in 6 mL deionized water.

D. DOX Loading and Release Test of Surface-Modified Lauric-Acid-Capped CoFe₂O₄ Nanoparticles

The drug-loading performance of water-soluble lauric-acid-capped CoFe₂O₄ NPs was characterized. A 0.03 mg of surface-modified lauric-acid-capped CoFe₂O₄ NPs were dispersed in 5 mL of the DOX diluted in ultra-pure PBS at 25 °C (concentration is 0.5 mg·mL⁻¹), and the solution was shaken for 24 h. Finally, the modified lauric-acid-capped CoFe₂O₄ NPs loaded with DOX were collected by centrifugation. The supernatant was analyzed by UV-Vis spectrophotometer measurement. The *in vitro* drug delivery test was carried out with different pH values at 37 °C. Typically, 5 mg of DOX-loaded lauric-acid-capped CoFe₂O₄ NPs were dipped into 10 mL and pH = 4 and 7.4 phosphoric acidic buffer solutions (PBS), respectively. At selected time intervals, the same volume solution was taken and immediately replaced with an equal volume of fresh PBS. The amount of released DOX in the taken PBS was determined using UV-Vis spectrophotometer at 480 nm.

E. Structural and Magnetic Characterization

The morphology and structure of the CoFe₂O₄ NPs were analyzed using a Philips CM-100 transmission electron microscope (TEM) operated at 100 kV. X-ray powder diffraction patterns of the NPs were collected on a Bruker

D8-Advance X-ray diffractometer (XRD) with Cu K α radiation ($\lambda = 1.5418 \text{ \AA}$). The zeta-potential measurements were conducted on a Zetasizer Nano ZS instrument (Malvern Instruments, Malvern, U.K). The surface modified and bare CoFe₂O₄ NPs were characterized by a Shimadzu Fourier transform infrared (FTIR)-8300 spectrometer. Magnetization curve measurements were carried out on a MicroSense vibrating sample magnetometer (VSM). The DOX loading and *in vitro* controlled release test were measured by UV spectrometer (Agilent Cary 60) at 480 nm.

III. RESULTS AND DISCUSSION

A. Synthesis of Lauric-Acid-Capped CoFe₂O₄ Nanoparticles

Morphology of lauric-acid-capped CoFe₂O₄ NPs was studied using TEM. The resulting CoFe₂O₄ NPs possessed an average size of 15.3 nm with a standard deviation of 1.7 nm, as shown in Fig. 2(a). The NPs can be slightly dissolved in water due to the use of lauric acid as surfactant (solubility in water = 55 mg/L at 20 °C). Crystal structures of the lauric-acid-capped CoFe₂O₄ NPs were identified by XRD, as shown in Fig. 2(b). The positions and intensities of the diffraction peaks coincide with the standard diffraction data of inverse spinel structured CoFe₂O₄.

The VSM was used to investigate the magnetic properties of the lauric-acid-capped CoFe₂O₄ NPs. The hysteresis loop of the lauric-acid-capped CoFe₂O₄ NPs is shown in Fig. 2(c); the saturation magnetization (M_s) of the as-synthesized NPs is 72 emu·g⁻¹ which is smaller than the value of CoFe₂O₄ bulk material (94 emu·g⁻¹) [24]. The coercivity of the CoFe₂O₄ is around 185 Oe, which is much larger than that of Fe₂O₃ NPs. This indicates that the magnetic anisotropy of the CoFe₂O₄ materials has been significantly improved because the Co cation is incorporated into the FeO matrix.

The dispersion behavior of the lauric-acid-capped CoFe₂O₄ NPs in water was investigated by observing the stability of NP suspension in aqueous medium, and the stability of the suspension sustained even after 48 h. The stable suspension of the CoFe₂O₄ NPs indicates the existence of the hydrogen bond between the aqueous solution and the lauric-acid layer. The aqueous solubility of the lauric-acid-capped CoFe₂O₄ NPs makes them an ideal candidate for various *in vivo* biomedical applications like cancer treatment [6].

B. Surface Modification of Lauric-Acid-Capped CoFe₂O₄ Nanoparticles

The surface modification process is illustrated in Fig. 1; the lauric-acid molecules can anchor on the CoFe₂O₄ NP surface through hydrogen bonds. The lauric-acid-capped CoFe₂O₄ NPs with great water solubility were achieved through surface modification with different surfactants, which has both nonpolar and polar groups, while the nonpolar groups bind with the lauric acid layer through strong van der Waals interactions, the polar groups can improve the dispersity of NPs in water. The TEM images of CTAB- and SDS-modified CoFe₂O₄ NPs are presented in Fig. 3(a) and (b). The modified CoFe₂O₄ NPs exhibit better uniformity and stability than bare NPs, indicating that surface modification is an effective strategy for




Fig. 2. (a) TEM image of lauric-acid-capped CoFe_2O_4 NPs (inset: histogram of particle size). (b) XRD patterns of lauric-acid-capped CoFe_2O_4 NPs. (c) Hysteresis loops at 300 K of lauric-acid-capped CoFe_2O_4 NPs (inset: stable NPs in aqueous solution).




Fig. 3. (a) TEM image of CTAB-modified lauric-acid-capped CoFe_2O_4 NPs. (b) TEM image of SDS-modified lauric-acid-capped CoFe_2O_4 NPs. (c) Zeta potential of CTAB- and SDS-modified lauric-acid-capped CoFe_2O_4 NPs.

phase transfer of CoFe_2O_4 NPs. The stability and interparticle electrostatic interactions of the NPs were determined by the surface charges of lauric-acid-capped CoFe_2O_4 in water which were characterized by the zeta-potential measurements. As shown in Fig. 3(c), the zeta potential of the bare lauric-acid-capped CoFe_2O_4 NPs is -16.2 mV while the zeta-potential values of the CTAB- and SDS-modified lauric-acid-capped CoFe_2O_4 NPs are around 34.8 and -26.6 mV, respectively. The high zeta-potential absolute values of CoFe_2O_4 NPs in water dispersions indicate their high stability after surfactant modification. The successful surface modification of CTAB and SDS on lauric-acid-capped CoFe_2O_4 NPs was confirmed by the FTIR spectra in Fig. 4. For CTAB-modified lauric-acid-capped CoFe_2O_4 NPs, the observed band at 603 cm^{-1} as shown in Fig. 4(a) corresponded to the intrinsic stretching vibrations of the metal at the tetrahedral site. The absorption band at 1465 cm^{-1} indicated the existence of $-\text{CH}_2-$ group of the CTAB [25], [26]. The FTIR spectrum in Fig. 4(b) confirmed that the CoFe_2O_4 NPs were successfully modified with CTAB. The characteristic bands at 989 and 1285 cm^{-1}




Fig. 4. FTIR of (a) as-synthesized lauric-acid-capped CoFe_2O_4 NPs, (b) CTAB-modified lauric-acid-capped CoFe_2O_4 NPs, and (c) SDS-modified lauric-acid-capped CoFe_2O_4 NPs.

in the range of 900 – 1600 cm^{-1} , as shown in Fig. 4(c), are associated with the sulfate group on the SDS surfactant. The absorption band at 1413 cm^{-1} corresponded to the scissoring of methylene group, indicating that the surfactants were successfully modified on the CoFe_2O_4 NPs [27], [28].

Magnetic hysteresis loops of both the CTAB- and SDS-modified CoFe_2O_4 NPs at room temperature are shown in Fig. 5. The saturation magnetization of the CTAB- and SDS-modified CoFe_2O_4 NPs are 38.5 and 33.6 $\text{emu} \cdot \text{g}^{-1}$, which are smaller than that of the pure CoFe_2O_4 NPs (72 $\text{emu} \cdot \text{g}^{-1}$) because of the additional mass of the nonmagnetic surfactants.

C. DOX Loading and Release Test of Surface-Modified Lauric-Acid-Capped CoFe_2O_4 Nanoparticles

DOX has been widely used in cancer treatment due to its great clinical effects in chemotherapy, but the dosage administered is strongly limited by their severe side effects [29]. The inverse spinel CoFe_2O_4 can efficiently loaded with the anticancer drug DOX by supramolecular π - π stacking interactions [30]. Herein, the loaded DOX on the modified lauric-acid-capped CoFe_2O_4 NPs in the PBS solution at




Fig. 5. VSM of CTAB-modified lauric-acid-capped CoFe_2O_4 NPs (blue curve) and SDS-modified lauric-acid-capped CoFe_2O_4 NPs (red curve).




Fig. 6. DOX loading efficiency of CTAB- and SDS-modified lauric-acid-capped CoFe_2O_4 NPs.

pH = 7.4 was studied. As shown in Fig. 6, the DOX loading efficiency of the CTAB- and SDS-modified lauric-acid-capped CoFe_2O_4 NPs were, respectively, 74.3% and 61.8%. The results confirmed the great drug-loading capacity of modified lauric-acid-capped CoFe_2O_4 NPs.

The *in vitro* drug release from the drug-loaded lauric-acid-capped CoFe_2O_4 NPs was studied with different pH values (Fig. 7). The results show that the release process of DOX from NPs can be triggered through tuning pH values. When the pH value of PBS solution is 7.4, the DOX on the lauric-acid-capped CoFe_2O_4 NPs remained stable; the cumulative DOX released from CTAB-modified and SDS-modified lauric-acid-capped CoFe_2O_4 NPs is less than 14% after immersion in PBS for 48 h. On the other hand, the CTAB-modified and SDS-modified lauric-acid-capped CoFe_2O_4 NPs exhibited a significant release of DOX when the pH value of solution is 4. The amount of DOX released from the CTAB-modified and SDS-modified lauric-acid-capped CoFe_2O_4 NPs increased to 56.1% and 48.2%, respectively; this was attributed to the improvement of water solubility and hydrophilicity of DOX in




Fig. 7. DOX release curves of CTAB- and SDS-modified lauric-acid-capped CoFe_2O_4 NPs at pH = 4 and pH = 7.4.

decreased pH value, which was caused by the increase in protonation of the ammonium groups on DOX [31], [32]. These values are similar to the previous reported results using related nanomaterials [33]. The pH-triggered drug-release mechanism of lauric-acid-capped CoFe_2O_4 NPs presents the potential for practical cancer therapy while minimizing the side effects to normal organs by releasing DOX only after entering the acidic microenvironments such as cancerous tissue.

IV. CONCLUSION

This paper reported a facile one-pot method to synthesize the monodisperse ferrite spinel lauric-acid-capped CoFe_2O_4 NPs. The lauric-acid-capped CoFe_2O_4 NPs with a particle size of 15.3 ± 1.7 nm were successfully synthesized. The phase transfer of lauric-acid-capped CoFe_2O_4 NPs through further surface modification in water with CTAB and SDS was achieved. The surface-modified lauric-acid-capped CoFe_2O_4 NPs also possessed high drug loading and excellent pH-responsive drug-release capability. These results reveal that water-soluble lauric-acid-capped CoFe_2O_4 NPs can be used as a potential drug delivery system due to its pH-sensitive drug-release properties.

ACKNOWLEDGMENT

This work was supported in part by the Seed Funding Program for Basic Research, the Seed Funding Program for Applied Research, and the Small Project Funding Program from The University of Hong Kong, Hong Kong, in part by RGC-GRF under Grant HKU 17204617, in part by the ITF Tier 3 Funding under Grant ITS-104/13 and Grant ITS-214/14, and in part by the University Grants Committee of HK under Grant AoE/P-04/08.

REFERENCES

- [1] C. Liu, B. Zou, A. J. Rondinone, and Z. J. Zhang, "Chemical control of superparamagnetic properties of magnesium and cobalt spinel ferrite nanoparticles through atomic level magnetic couplings," *J. Amer. Chem. Soc.*, vol. 122, no. 26, pp. 6263–6267, 2000.

- [2] K. K. Mohaideen and P. A. Joy, "High magnetostriction and coupling coefficient for sintered cobalt ferrite derived from superparamagnetic nanoparticles," *Appl. Phys. Lett.*, vol. 101, no. 7, pp. 072405-2-072405-6, 2012.
- [3] A. J. Rondinone, A. C. S. Samia, and Z. J. Zhang, "Superparamagnetic relaxation and magnetic anisotropy energy distribution in CoFe_2O_4 spinel ferrite nanocrystallites," *J. Phys. Chem. B*, vol. 103, no. 33, pp. 6876-6880, 1999.
- [4] S. T. Xu, Y. Q. Ma, G. H. Zheng, and Z. X. Dai, "Simultaneous effects of surface spins: Rarely large coercivity, high remanence magnetization and jumps in the hysteresis loops observed in CoFe_2O_4 nanoparticles," *Nanoscale*, vol. 7, no. 15, pp. 6520-6526, 2015.
- [5] J. Carrey, B. Mehdaoui, and M. Respaud, "Simple models for dynamic hysteresis loop calculations of magnetic single-domain nanoparticles: Application to magnetic hyperthermia optimization," *J. Appl. Phys.*, vol. 109, no. 8, p. 083921, 2011.
- [6] U. Häfeli, W. Schütt, J. Teller, and M. Zborowski, *Scientific and Clinical Applications of Magnetic Carriers*. Berlin, Germany: Springer, 2013.
- [7] P. Oswald, O. Clement, C. Chambon, E. Schouman-Claeys, and G. Frija, "Liver positive enhancement after injection of superparamagnetic nanoparticles: Respective role of circulating and uptaken particles," *Magn. Reson. Imag.*, vol. 15, no. 9, pp. 1025-1031, 1997.
- [8] D. G. Mitchell, "MR imaging contrast agents—What's in a name?" *J. Magn. Reson. Imag.*, vol. 7, no. 1, pp. 1-4, 1997.
- [9] M. A. Willard, L. K. Kurihara, E. E. Carpenter, S. Calvin, and V. G. Harris, "Chemically prepared magnetic nanoparticles," *Int. Mater. Rev.*, vol. 49, nos. 3-4, pp. 125-170, 2004.
- [10] Z. Xu, C. Shen, Y. Hou, H. Gao, and S. Sun, "Oleylamine as both reducing agent and stabilizer in a facile synthesis of magnetite nanoparticles," *Chem. Mater.*, vol. 21, no. 9, pp. 1778-1780, 2009.
- [11] R. T. Olsson, G. Salazar-Alvarez, M. S. Hedenqvist, U. W. Gedde, F. Lindberg, and S. J. Savage, "Controlled synthesis of near-stoichiometric cobalt ferrite nanoparticles," *Chem. Mater.*, vol. 17, no. 20, pp. 5109-5118, 2005.
- [12] A. J. Rondinone, A. C. S. Samia, and Z. J. Zhang, "A chemometric approach for predicting the size of magnetic spinel ferrite nanoparticles from the synthesis conditions," *J. Phys. Chem. B*, vol. 104, no. 33, pp. 7919-7922, 2000.
- [13] G. V. M. Jacintho, A. G. Brolo, P. Corio, P. A. Z. Suarez, and J. C. Rubim, "Structural investigation of MFe_2O_4 (M = Fe, Co) magnetic fluids," *J. Phys. Chem. C*, vol. 113, no. 18, pp. 7684-7691, 2009.
- [14] H. Qu, H. Ma, A. Riviere, W. Zhou, and C. J. O'Connor, "One-pot synthesis in polyamines for preparation of water-soluble magnetite nanoparticles with amine surface reactivity," *J. Mater. Chem.*, vol. 22, no. 8, pp. 3311-3313, 2012.
- [15] X. Michalet *et al.*, "Quantum dots for live cells, *in vivo* imaging, and diagnostics," *Science*, vol. 307, no. 5709, pp. 538-544, 2005.
- [16] I. L. Medintz, H. T. Uyeda, E. R. Goldman, and H. Mattoussi, "Quantum dot bioconjugates for imaging, labelling and sensing," *Nature Mater.*, vol. 4, no. 6, pp. 435-446, 2005.
- [17] Q. Liang, D. Zhao, T. Qian, K. Freeland, and Y. Feng, "Effects of stabilizers and water chemistry on arsenate sorption by polysaccharide-stabilized magnetite nanoparticles," *Ind. Eng. Chem. Res.*, vol. 51, no. 5, pp. 2407-2418, 2012.
- [18] A. Swami, A. Kumar, and M. Sastry, "Formation of water-dispersible gold nanoparticles using a technique based on surface-bound interdigitated bilayers," *Langmuir*, vol. 19, no. 4, pp. 1168-1172, 2003.
- [19] C. H. Kim *et al.*, "Electronic structure of vertically aligned Mn-doped CoFe_2O_4 nanowires and their application as humidity sensors and photodetectors," *J. Phys. Chem. C*, vol. 113, no. 17, pp. 7085-7090, 2009.
- [20] J. Li, M. Chen, Z. Gao, J. Du, W. Yang, and M. Yin, "Effective approach towards Si-bilayer-IDA modified CoFe_2O_4 magnetic nanoparticles for high efficient protein separation," *Colloids Surf. B, Biointerfaces*, vol. 146, pp. 468-474, Oct. 2016.
- [21] D. K. Kim, Y. Zhang, J. Kehr, T. Klason, B. Bjelke, and M. Muhammed, "Characterization and MRI study of surfactant-coated superparamagnetic nanoparticles administered into the rat brain," *J. Magn. Magn. Mater.*, vol. 225, nos. 1-2, pp. 256-261, 2001.
- [22] S. Sun *et al.*, "Monodisperse MFe_2O_4 (M=Fe, Co, Mn) nanoparticles," *J. Amer. Chem. Soc.*, vol. 126, no. 1, pp. 273-279, 2004.
- [23] B. Bateer *et al.*, "Synthesis, size and magnetic properties of controllable MnFe_2O_4 nanoparticles with versatile surface functionalities," *Dalton Trans.*, vol. 43, no. 26, pp. 9885-9891, 2014.
- [24] B. Debnath, A. Bansal, H. G. Salunke, A. Sadhu, and S. Bhattacharyya, "Enhancement of magnetization through interface exchange interactions of confined NiO nanoparticles within the mesopores of CoFe_2O_4 ," *J. Phys. Chem. C*, vol. 120, no. 10, pp. 5523-5533, 2016.
- [25] K. D. Dobson, A. D. Roddick-Lanzilotta, and A. J. McQuillan, "An *in situ* infrared spectroscopic investigation of adsorption of sodium dodecylsulfate and of cetyltrimethylammonium bromide surfactants to TiO_2 , ZrO_2 , Al_2O_3 , and Ta_2O_5 particle films from aqueous solutions," *Vibrational Spectrosc.*, vol. 24, no. 2, pp. 287-295, 2000.
- [26] A. Baykal, N. Kasapoğlu, Y. Köseoğlu, M. S. Toprak, and H. Bayrakdar, "CTAB-assisted hydrothermal synthesis of NiFe_2O_4 and its magnetic characterization," *J. Alloys Compounds*, vol. 464, nos. 1-2, pp. 514-518, 2008.
- [27] M. Singh, H. S. Dosanjh, and H. Singh, "Surface modified spinel cobalt ferrite nanoparticles for cationic dye removal: Kinetics and thermodynamics studies," *J. Water Process Eng.*, vol. 11, pp. 152-161, Jun. 2016.
- [28] M. Vadivel, R. R. Babu, M. Arivanandhan, K. Ramamurthi, and Y. Hayakawa, "Role of SDS surfactant concentrations on the structural, morphological, dielectric and magnetic properties of CoFe_2O_4 nanoparticles," *RSC Adv.*, vol. 5, no. 34, pp. 27060-27068, 2015.
- [29] D. Wang and S. J. Lippard, "Cellular processing of platinum anticancer drugs," *Nature Rev. Drug Discovery*, vol. 4, no. 4, pp. 307-320, 2005.
- [30] Z. Liu, X. Sun, N. Nakayama-Ratchford, and H. Dai, "Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery," *ACS Nano*, vol. 1, no. 1, pp. 50-56, 2007.
- [31] L. Y. Qiu and M. Q. Yan, "Constructing doxorubicin-loaded polymeric micelles through amphiphilic graft polyphosphazenes containing ethyl tryptophan and PEG segments," *Acta Biomaterialia*, vol. 5, no. 6, pp. 2132-2141, 2009.
- [32] F. H. Chen, Q. Gao, and J. Z. Ni, "The grafting and release behavior of doxorubicin from Fe_3O_4 SiO_2 core-shell structure nanoparticles via an acid cleaving amide bond: The potential for magnetic targeting drug delivery," *Nanotechnology*, vol. 19, no. 16, p. 165103, 2008.
- [33] G. Wang, Y. Ma, Z. Wei, and M. Qi, "Development of multifunctional cobalt ferrite/graphene oxide nanocomposites for magnetic resonance imaging and controlled drug delivery," *Chem. Eng. J.*, vol. 289, pp. 150-160, Apr. 2016.